A First‐In‐Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM‐S401, a Novel siRNA‐DegradaBALL Drug Targeting CTGF in Healthy Adults

Documenti analoghi

• Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects
  di: Young‐Sim Choi, et al.
  Pubblicazione: (2025)
• Diffusion Tractography Biomarker for Epilepsy Severity in Children With Drug‐Resistant Epilepsy
  di: Jeong‐Won Jeong, et al.
  Pubblicazione: (2025)
• Engineered lung cell targeting and SLC7A11 siRNA expressing bacterial extracellular vesicles impair the progression of none‐small cell lung cancer
  di: Xiao‐dan Wan, et al.
  Pubblicazione: (2025)
• A Long‐Term Human Liver Spheroid Model for Assessing Silencing and Durability of GalNAc ‐Conjugated siRNAs
  di: Gijs‐Jan Scholten, et al.
  Pubblicazione: (2026)
• Safety, Tolerability, and Pharmacokinetics of Single and Multiple Topical Applications of Sodium Taurodeoxycholate, a Treatment for Atopic Dermatitis
  di: Heejae Won, et al.
  Pubblicazione: (2025)